Search research articles
Contact Us
Filters
Showing results (91-100 of 126) with videos related to
Page
of 13
Sort By:
Cancer Research
|
September 23, 2003
Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity
Jerome Bertherat, Lionel Groussin, Fabiano Sandrini, et al.
European Journal of Endocrinology
|
October 7, 2022
Corticotroph tumor progression speed after adrenalectomy
Laura Bessiène, Sandrine Moutel, Marine Lataud, et al.
American Journal of Human Genetics
|
November 9, 2002
Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD
Lionel Groussin, Lawrence S Kirschner, Caroline Vincent-Dejean, et al.
Pituitary
|
November 7, 2015
Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease
Maria Fleseriu, Rosario Pivonello, Jacques Young, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 19, 2010
Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors
Stéphane Bonnet, Sébastien Gaujoux, Pierre Launay, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 23, 2004
Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy
Florence de Fraipont, Michelle El Atifi, Nadia Cherradi, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 22, 2015
Hormonal, Radiological, NP-59 Scintigraphy, and Pathological Correlations in Patients With Cushing's Syndrome Due to Primary Pigmented Nodular Adrenocortical Disease (PPNAD)
Delphine Vezzosi, Florence Tenenbaum, Laure Cazabat, et al.
Annals of Surgery
|
December 25, 2007
Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors
Patsy S H Soon, Rossella Libe, Diana E Benn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2010
β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma
Sébastien Gaujoux, Sophie Grabar, Martin Fassnacht, et al.
European Journal of Endocrinology
|
July 4, 2025
Progression of potentially aggressive pituitary neuroendocrine tumors after radiotherapy: risk factors, management, and outcomes
Fabio Bioletto, Caroline Bogeat, Maxime Barat, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 126) with videos related to
Sort By:
Page
of 13
Cancer Research
|
September 23, 2003
Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity
Jerome Bertherat, Lionel Groussin, Fabiano Sandrini, et al.
European Journal of Endocrinology
|
October 7, 2022
Corticotroph tumor progression speed after adrenalectomy
Laura Bessiène, Sandrine Moutel, Marine Lataud, et al.
American Journal of Human Genetics
|
November 9, 2002
Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD
Lionel Groussin, Lawrence S Kirschner, Caroline Vincent-Dejean, et al.
Pituitary
|
November 7, 2015
Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease
Maria Fleseriu, Rosario Pivonello, Jacques Young, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 19, 2010
Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors
Stéphane Bonnet, Sébastien Gaujoux, Pierre Launay, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 23, 2004
Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy
Florence de Fraipont, Michelle El Atifi, Nadia Cherradi, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 22, 2015
Hormonal, Radiological, NP-59 Scintigraphy, and Pathological Correlations in Patients With Cushing's Syndrome Due to Primary Pigmented Nodular Adrenocortical Disease (PPNAD)
Delphine Vezzosi, Florence Tenenbaum, Laure Cazabat, et al.
Annals of Surgery
|
December 25, 2007
Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors
Patsy S H Soon, Rossella Libe, Diana E Benn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2010
β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma
Sébastien Gaujoux, Sophie Grabar, Martin Fassnacht, et al.
European Journal of Endocrinology
|
July 4, 2025
Progression of potentially aggressive pituitary neuroendocrine tumors after radiotherapy: risk factors, management, and outcomes
Fabio Bioletto, Caroline Bogeat, Maxime Barat, et al.
Page
of 13